Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2016 1
2017 1
2018 3
2019 1
2020 4
2021 2
2022 10
2023 7
2024 15
2025 22
2026 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean jennifer r brown AND cardiovascular (11 results)?
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B; BaxHTN Investigators. Flack JM, et al. Among authors: brown jm. N Engl J Med. 2025 Oct 9;393(14):1363-1374. doi: 10.1056/NEJMoa2507109. Epub 2025 Aug 30. N Engl J Med. 2025. PMID: 40888730 Free PMC article. Clinical Trial.
The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study.
Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. Brown JM, et al. Ann Intern Med. 2020 Jul 7;173(1):10-20. doi: 10.7326/M20-0065. Epub 2020 May 26. Ann Intern Med. 2020. PMID: 32449886 Free PMC article.
BACKGROUND: Primary aldosteronism is a nonsuppressible renin-independent aldosterone production that causes hypertension and cardiovascular disease. OBJECTIVE: To characterize the prevalence of nonsuppressible renin-independent aldosterone production, as well as biochemica …
BACKGROUND: Primary aldosteronism is a nonsuppressible renin-independent aldosterone production that causes hypertension and cardiovascul …
Primary Aldosteronism: State-of-the-Art Review.
Vaidya A, Hundemer GL, Nanba K, Parksook WW, Brown JM. Vaidya A, et al. Among authors: brown jm. Am J Hypertens. 2022 Dec 8;35(12):967-988. doi: 10.1093/ajh/hpac079. Am J Hypertens. 2022. PMID: 35767459 Free PMC article.
In the past 2 decades, we have learned that PA is a highly prevalent syndrome that is largely attributable to pathogenic somatic mutations, that contributes to cardiovascular, metabolic, and kidney disease, and that when recognized, can be adequately treated with widely av …
In the past 2 decades, we have learned that PA is a highly prevalent syndrome that is largely attributable to pathogenic somatic mutations, …
New drug therapies for hypertension.
Azizi M, Tuttle KR, Brown JM, Piskorz DL, Kario K, Williams B. Azizi M, et al. Among authors: brown jm. Lancet. 2026 Mar 7;407(10532):1014-1028. doi: 10.1016/S0140-6736(25)02064-1. Epub 2026 Feb 10. Lancet. 2026. PMID: 41687677 Review.
These therapies include small interfering RNA agents that inhibit angiotensinogen synthesis as a novel approach to inhibit the renin-angiotensin system, and new strategies to more selectively modulate aldosterone, such as aldosterone synthase inhibitors and non-steroidal m …
These therapies include small interfering RNA agents that inhibit angiotensinogen synthesis as a novel approach to inhibit the renin-angiote …
Biomarkers to Guide Medical Therapy in Primary Aldosteronism.
Hundemer GL, Leung AA, Kline GA, Brown JM, Turcu AF, Vaidya A. Hundemer GL, et al. Among authors: brown jm. Endocr Rev. 2024 Jan 4;45(1):69-94. doi: 10.1210/endrev/bnad024. Endocr Rev. 2024. PMID: 37439256 Free PMC article. Review.
It is crucial that clinicians recognize that multimodal medical treatment for PA can be highly effective at reducing the risk for adverse cardiovascular and kidney outcomes when titrated with intention. The key biomarkers reflective of optimized medical therapy are unsurpr …
It is crucial that clinicians recognize that multimodal medical treatment for PA can be highly effective at reducing the risk for adverse …
Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study.
Hundemer GL, Agharazii M, Madore F, Vaidya A, Brown JM, Leung AA, Kline GA, Larose E, Piché ME, Crean AM, Shaw JLV, Ramsay T, Hametner B, Wassertheurer S, Sood MM, Hiremath S, Ruzicka M, Goupil R. Hundemer GL, et al. Among authors: brown jm. Circulation. 2024 Jan 9;149(2):124-134. doi: 10.1161/CIRCULATIONAHA.123.066389. Epub 2023 Nov 30. Circulation. 2024. PMID: 38031887 Free PMC article.
BACKGROUND: Primary aldosteronism, characterized by overt renin-independent aldosterone production, is a common but underrecognized form of hypertension and cardiovascular disease. Growing evidence suggests that milder and subclinical forms of primary aldosteronism are hig …
BACKGROUND: Primary aldosteronism, characterized by overt renin-independent aldosterone production, is a common but underrecognized form of …
Subclinical primary aldosteronism.
Parisien-La Salle S, Brown JM, Tsai CH, Hundemer GL, Vaidya A. Parisien-La Salle S, et al. Among authors: brown jm. Arch Endocrinol Metab. 2025 Nov 28;70(Spec 1):e250400. doi: 10.20945/2359-4292-2025-0400. Arch Endocrinol Metab. 2025. PMID: 41312955 Free PMC article. Review.
Primary aldosteronism (PA) is a major contributor to hypertension and cardiovascular disease. Subclinical PA, a preclinical or early manifestation of PA, has been identified in individuals with normal blood pressure and in those with mild hypertension without signs or symp …
Primary aldosteronism (PA) is a major contributor to hypertension and cardiovascular disease. Subclinical PA, a preclinical or early …
Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.
Azizi M, Brown JM, Dwyer JP, Flack JM, Jones ESW, Kurlyandskaya R, Li H, Birve F, Lihn AS, Perl S, Schlaich MP, Shibata H, Wang JG, Williams B; Bax24 investigators. Azizi M, et al. Among authors: brown jm. Lancet. 2026 Mar 7;407(10532):988-999. doi: 10.1016/S0140-6736(25)02549-8. Lancet. 2026. PMID: 41794437 Free article. Clinical Trial.
Redefining Primary Aldosteronism.
Vaidya A, Brown JM. Vaidya A, et al. Among authors: brown jm. J Am Coll Cardiol. 2026 May 26;87(20):2861-2863. doi: 10.1016/j.jacc.2026.02.5090. Epub 2026 Mar 25. J Am Coll Cardiol. 2026. PMID: 41879587 No abstract available.
80 results